OIS@AAO 2017 Videos

Kala Pharmaceuticals is expecting by the end of 2017 topline clinical data from its ongoing Phase III trial of KPI-121 0.25% for treatment of dry…

Clearside Biomedical has a full agenda of major near-term milestones in the development of its suprachoroidal CLS-TA (triamcinolone-acetonide) platform in 2018 and 2019, president and…

Alimera Sciences’ Iluvien insert for treatment of diabetic macular edema is making headway in the market, CEO Dan Myers said at the Company Showcase 3…

Even though its PDUFA date for the glaucoma agent Rhopressa is set for February 2018, Aerie Pharmaceuticals is moving forward on development of its age-related…

Notal Vision is set to launch its second product, home-based optical coherence tomography (OTC) for monitoring of retinal fluid accumulation in patients with retinal disease,…

Ocular Therapeutix is gearing up to resubmit in the first half of 2018 its New Drug Application for its Dextenza 0.4-mg dexamethasone insert, president and…

Graybug Vision’s ongoing Phase I/II trial or GB-102 (1 mg sunitinib) injection for wet age-related macular degeneration should produce initial six-month data in Q2 2018,…

Allegro Ophthalmics is planning a 2018 Phase III trial of its lead integrin peptide therapy candidate Luminate for treatment of diabetic macular edema, president Vicken…

Ocunexus Therapeutics’ CEO Brian Levy, OD, MSc, provided an update on Ocunexus Therapeutics’ two lead candidates during the Company Showcase 3 session at OIS@AAO 2017.…

During the Company Showcase 3 session at OIS@AAO 2017 KalVista Pharmaceuticals CEO Andrew Crockett provided an update on the company’s collaboration with Merck for KVD001,…

In developing the small-molecule agent AKB-9778 to target the Tie2/VE-PTP pathway, Aerpio president and CEO Joseph Gardner, PhD, said the first-in-class agent that inhibits phosophatase…

ONL Therapeutics is using the $5 million in Series A funding it obtained in May 2017 to complete and file the investigational new drug application…